CVRx Nominates Former Axogen CEO Michael Dale to Board Before June 1 Annual Meeting
CVRx nominated Michael Dale, former Axogen CEO, to its board ahead of its June 1, 2026 annual meeting. Dale’s leadership in medical devices, including Abbott’s structural heart division, is expected to bolster Barostim adoption in heart failure therapy.
1. Board Nomination Details
CVRx announced the nomination of Michael Dale to its board ahead of the June 1, 2026 annual meeting, when stockholders will vote on his election.
2. Michael Dale’s Professional Background
Dale has served as CEO and President of Axogen since August 2024 and previously led Abbott’s structural heart division for eight years, with earlier leadership roles at GI Dynamics, St. Jude Medical and other medical device firms.
3. Implications for Barostim Adoption
Dale brings a track record of commercializing medical devices, which CVRx expects will accelerate adoption of its Barostim system and support the company’s growth in heart failure therapy.